1. With MEDI 's potential buy-out value of 10B+, how does this affect valuations of other similar biotechs? If MEDI is worth 10B+ in a buyout, then BIIB would appear undervalued (IMO).
2. Any possibility of a large cap bio (like AMGN) being a bidder for MEDI.
3. Any ideas on how a MEDI buy-out would be structured (cash, stock, both)? I would think it would be an all cash deal.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.